Leucine Rich Bio, a microbiome company, secured an undisclosed sum in a pre-series A round of funding. Prominent medical professionals, including gastroenterologists, oncologists, and biotech entrepreneurs, were the driving force behind the funding.
The funding will mostly be used for the creation of new products and branding. This investment will aid the business in expanding its line of products and strengthening its R&D capabilities.
Read also - [Funding alert] Vastu Housing Finance Secures $30 Mn Funding From Faering Capital
Commenting on the investment, Kumar Sankaran, CEO of Leucine Rich Bio, stated, "We truly believe in the transformative potential of the microbiome in shaping the future of healthcare, especially cancer treatment and care. With this support, we are poised to take significant strides in our mission to harness the power of the microbiome to combat various chronic diseases and cancer."
The first microbiome business in South Asia is known as Leucine Rich Bio Pvt Ltd. The company, which has its headquarters in Bengaluru, has been a leader in the creation and standardisation of cutting-edge analytics tools for the analysis and interpretation of complex genomics data since its founding in 2014.
Read also - [Funding alert] Vastu Housing Finance Secures $30 Mn Funding From Faering Capital
About Leucine Rich Bio
Under this brand, the company plans to soon release additional supplements based on Indian microbiome data that address different diseases or conditions. Leucine Rich Bio is honoured to have won the Government of India's National Startup Award for 2021 in the "Health and Wellness" sector. The "Frost & Sullivan award" was given to Leucine Rich Bio in 2016 for its cloud-enabled genomics technology in the APAC region. In 2019, it was given to it for its innovation in microbiome diagnostics.
Read also - Amazon, Microsoft Partners with CBI to Fight Tech Support Fraud